Adaptive phage therapeutics (APT) is a clinical-stage biotechnology company advancing therapies to treat multi-drug resistant infections. Prior approaches in antimicrobials have been ‘fixed’ while the pathogens continue to evolve resistance – therefore all have either become obsolete or are becoming obsolete due to antimicrobial resistance. APT’s PhageBank approach leverages an ever-expanding library of phages that collectively provide an evergreen broad-spectrum and polymicrobial coverage. PhageBank therapy is matched through a proprietary phage susceptibility assay that APT has teamed with Mayo Clinic Laboratories to commercialize on a global scale.
PhageBank is positioned to be the first antimicrobial to increase in the spectrum of coverage and does not require market-suppressing antibiotic stewardship. Advanced development of APT’s therapeutics are funded in part by the US Dept of Defense.
Bacteriophage product pipeline:
- Prosthetic Joint Infection (PJI)
- Chronic Recurrent UTI
- Chronic Wound w/Osteomyelitis
PhageBank Companion Diagnostics
- HRQT Phage Susceptibility Test
- COVID-19 Vaccine